Topical Bevacizumab in the Treatment of Corneal Neovascularization

Dastjerdi, Mohammad H.; Alarfaj, Khalid; Nallasamy, Nambi; Hamrah, Pedram; Jurkūnas, Ūla V.; Pineda, Roberto; Pavan-Langston, Deborah; Dana, Reza

doi:10.1001/archophthalmol.2009.18

Cited by 170 publications

(78 citation statements)

References 30 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Significant lumen constriction was noted during the first week of regression in both our rat model and case report, echoing findings in earlier studies [10,15,22,28]. In vivo observation on days 7 and 21, however, revealed more vessels with visible flow than were visible in high magnification photographs.…”

Section: In Vivo Imaging Of Human Corneal Capillary Regression: Reporsupporting

confidence: 90%

“…Two rats were sutured and treated with one drop of topical bevacizumab (5 mg/ml) 4 times daily [22,24,25,29] and were followed for 7 days.…”

Section: Effectiveness Of Bevacizumab In a Rat Corneal Inflammation Mmentioning

confidence: 99%

“…In the literature there are some controversy concerning the effect of bevacizumab on murine VEGF-A [16,25,27,28,31,32,35]. The effect of bevacizumab on murine VEGF, is possibly route and species dependent [16,22,25,28,31,32].…”

Section: In Vivo Imaging Of Human Corneal Capillary Regression: Repormentioning

confidence: 99%

“…Steroids have long been used to promote the regression of undesirable neovessels and are well known for their anti-inflammatory and antiangiogenic effect [15][16][17]. More recently, bevacizumab, a monoclonal VEGF-A antibody approved for the treatment of metastatic colorectal cancer, has been widely used off-label to successfully induce regression in eye-related angiogenesis in cases of choroidal, retinal and corneal neovascularization in patients [18][19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

“…In both clinical and experimental studies, corneal capillary regression is commonly evaluated by degree of vascular invasion at the tissue level, using photography of visible blood vessels, fluorescein angiography, or by immunostaining of vascular endothelium at fixed time points [17,[21][22][23][24][25][26][27][28][29][30][31][32]. Little, however, is known about the morphologic characteristics of regressing capillaries at the cellular level following therapy.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model

2011

View full text Add to dashboard Cite

Abstract:In this study, we introduce a technique for repeated, microscopic observation of single regressing capillaries in vivo in inflamed murine corneas. Natural capillary regression was initiated by removal of inflammatory stimulus during an active pro-angiogenic phase, while the additional impact of anti-angiogenic treatment with triamcinolone or bevazicumab was investigated. Capillaries regressed naturally within one week and treatments did not further enhance the natural regression. Morphologically, early-phase regression was characterized by significant lumen narrowing and a significant reduction in CD11b+ myeloid cell infiltration of the extracellular matrix. By one week, vascular remodeling occurred concomitant with CD11b+CD68+KiM2R+ mature macrophage localization on capillary walls. Empty conduits without blood flow, positive for collagen IV and devoid of vascular endothelium and pericytes, were apparent in vivo and by three weeks were more numerous than perfused capillaries. By three weeks, macrophages aggregated around remaining perfused capillaries and were observed in apposition with degrading capillary segments. Abrupt termination of capillary sprouting in our regression model further revealed vascular endothelial abandonment of sprout tips and perfused capillary loop formation within a single angiogenic sprout, possibly as an intussusceptive response to cessation of the stimulus. Finally, we observed lumen constriction and macrophage localization on capillary walls in vivo in a clinical case of corneal capillary regression that paralleled findings in our murine model.

show abstract

Section: In Vivo Imaging Of Human Corneal Capillary Regression: Reporsupporting

confidence: 90%

“…Two rats were sutured and treated with one drop of topical bevacizumab (5 mg/ml) 4 times daily [22,24,25,29] and were followed for 7 days.…”

Section: Effectiveness Of Bevacizumab In a Rat Corneal Inflammation Mmentioning

confidence: 99%